The LD50 of calcium polycarbophil in young adult rats approximated 20 g/kg.
Calcium polycarbophil is a stool stabilizer. Based on its chemical structure, it is a synthetic polymer of polyacrylic acid cross-linked with divinyl glycol presenting a calcium atom as a counter-ion. Polycarbophil is used to treat constipation. This drug may also be used to help relieve the symptoms of irritable bowel syndrome or diarrhea.
Less gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali. The material possesses exceptionally high water-binding capacity. is not absorbed, does not interfere with the activity of digestive enzymes or intestinal absorption, possesses satisfactory stability, is physiologically inert, and does not cause gastrointestinal irritation.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Grepafloxacin | Calcium polycarbophil can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Enoxacin | Calcium polycarbophil can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pefloxacin | Calcium polycarbophil can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ciprofloxacin | Calcium polycarbophil can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Trovafloxacin | Calcium polycarbophil can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nalidixic acid | Calcium polycarbophil can cause a decrease in the absorption of Nalidixic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rosoxacin | Calcium polycarbophil can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cinoxacin | Calcium polycarbophil can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lomefloxacin | Calcium polycarbophil can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gatifloxacin | Calcium polycarbophil can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Norfloxacin | Calcium polycarbophil can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gemifloxacin | Calcium polycarbophil can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ofloxacin | Calcium polycarbophil can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sparfloxacin | Calcium polycarbophil can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Temafloxacin | Calcium polycarbophil can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fleroxacin | Calcium polycarbophil can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Technetium Tc-99m ciprofloxacin | Calcium polycarbophil can cause a decrease in the absorption of Technetium Tc-99m ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Garenoxacin | Calcium polycarbophil can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nemonoxacin | Calcium polycarbophil can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Flumequine | Calcium polycarbophil can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Enrofloxacin | Calcium polycarbophil can cause a decrease in the absorption of Enrofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Orbifloxacin | Calcium polycarbophil can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sarafloxacin | Calcium polycarbophil can cause a decrease in the absorption of Sarafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Difloxacin | Calcium polycarbophil can cause a decrease in the absorption of Difloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pazufloxacin | Calcium polycarbophil can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Prulifloxacin | Calcium polycarbophil can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Delafloxacin | Calcium polycarbophil can cause a decrease in the absorption of Delafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sitafloxacin | Calcium polycarbophil can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Oxolinic acid | Calcium polycarbophil can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rufloxacin | Calcium polycarbophil can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pipemidic acid | Calcium polycarbophil can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Deferiprone | The serum concentration of Deferiprone can be decreased when it is combined with Calcium polycarbophil. |
| Dobutamine | The therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium polycarbophil. |
| Dolutegravir | The serum concentration of Dolutegravir can be decreased when it is combined with Calcium polycarbophil. |
| Eltrombopag | The serum concentration of Eltrombopag can be decreased when it is combined with Calcium polycarbophil. |
| Estramustine | Calcium polycarbophil can cause a decrease in the absorption of Estramustine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Calcium acetate | The risk or severity of adverse effects can be increased when Calcium polycarbophil is combined with Calcium acetate. |
| Digoxin | Calcium polycarbophil may increase the arrhythmogenic and cardiotoxic activities of Digoxin. |
| Acetyldigitoxin | Calcium polycarbophil may increase the arrhythmogenic and cardiotoxic activities of Acetyldigitoxin. |
| Deslanoside | Calcium polycarbophil may increase the arrhythmogenic and cardiotoxic activities of Deslanoside. |
| Ouabain | Calcium polycarbophil may increase the arrhythmogenic and cardiotoxic activities of Ouabain. |
| Digitoxin | Calcium polycarbophil may increase the arrhythmogenic and cardiotoxic activities of Digitoxin. |
| Oleandrin | Calcium polycarbophil may increase the arrhythmogenic and cardiotoxic activities of Oleandrin. |
| Cymarin | Calcium polycarbophil may increase the arrhythmogenic and cardiotoxic activities of Cymarin. |
| Proscillaridin | Calcium polycarbophil may increase the arrhythmogenic and cardiotoxic activities of Proscillaridin. |
| Metildigoxin | Calcium polycarbophil may increase the arrhythmogenic and cardiotoxic activities of Metildigoxin. |
| Lanatoside C | Calcium polycarbophil may increase the arrhythmogenic and cardiotoxic activities of Lanatoside C. |
| Gitoformate | Calcium polycarbophil may increase the arrhythmogenic and cardiotoxic activities of Gitoformate. |
| Acetyldigoxin | Calcium polycarbophil may increase the arrhythmogenic and cardiotoxic activities of Acetyldigoxin. |
| Peruvoside | Calcium polycarbophil may increase the arrhythmogenic and cardiotoxic activities of Peruvoside. |
| Strontium ranelate | The serum concentration of Strontium ranelate can be decreased when it is combined with Calcium polycarbophil. |
| Doxycycline | The serum concentration of Doxycycline can be decreased when it is combined with Calcium polycarbophil. |
| Lymecycline | The serum concentration of Lymecycline can be decreased when it is combined with Calcium polycarbophil. |
| Clomocycline | The serum concentration of Clomocycline can be decreased when it is combined with Calcium polycarbophil. |
| Oxytetracycline | The serum concentration of Oxytetracycline can be decreased when it is combined with Calcium polycarbophil. |
| Demeclocycline | The serum concentration of Demeclocycline can be decreased when it is combined with Calcium polycarbophil. |
| Tetracycline | The serum concentration of Tetracycline can be decreased when it is combined with Calcium polycarbophil. |
| Metacycline | The serum concentration of Metacycline can be decreased when it is combined with Calcium polycarbophil. |
| Minocycline | The serum concentration of Minocycline can be decreased when it is combined with Calcium polycarbophil. |
| Sarecycline | The serum concentration of Sarecycline can be decreased when it is combined with Calcium polycarbophil. |
| Omadacycline | The serum concentration of Omadacycline can be decreased when it is combined with Calcium polycarbophil. |
| Penimepicycline | The serum concentration of Penimepicycline can be decreased when it is combined with Calcium polycarbophil. |
| Methyclothiazide | Methyclothiazide may decrease the excretion rate of Calcium polycarbophil which could result in a higher serum level. |
| Chlorthalidone | Chlorthalidone may decrease the excretion rate of Calcium polycarbophil which could result in a higher serum level. |
| Bendroflumethiazide | Bendroflumethiazide may decrease the excretion rate of Calcium polycarbophil which could result in a higher serum level. |
| Metolazone | Metolazone may decrease the excretion rate of Calcium polycarbophil which could result in a higher serum level. |
| Benzthiazide | Benzthiazide may decrease the excretion rate of Calcium polycarbophil which could result in a higher serum level. |
| Hydroflumethiazide | Hydroflumethiazide may decrease the excretion rate of Calcium polycarbophil which could result in a higher serum level. |
| Indapamide | Indapamide may decrease the excretion rate of Calcium polycarbophil which could result in a higher serum level. |
| Chlorothiazide | Chlorothiazide may decrease the excretion rate of Calcium polycarbophil which could result in a higher serum level. |
| Hydrochlorothiazide | Hydrochlorothiazide may decrease the excretion rate of Calcium polycarbophil which could result in a higher serum level. |
| Trichlormethiazide | Trichlormethiazide may decrease the excretion rate of Calcium polycarbophil which could result in a higher serum level. |
| Polythiazide | Polythiazide may decrease the excretion rate of Calcium polycarbophil which could result in a higher serum level. |
| Quinethazone | Quinethazone may decrease the excretion rate of Calcium polycarbophil which could result in a higher serum level. |
| Cyclopenthiazide | Cyclopenthiazide may decrease the excretion rate of Calcium polycarbophil which could result in a higher serum level. |
| Epitizide | Epitizide may decrease the excretion rate of Calcium polycarbophil which could result in a higher serum level. |
| Triethylenetetramine | Calcium polycarbophil can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Calcitriol | The risk or severity of adverse effects can be increased when Calcitriol is combined with Calcium polycarbophil. |
| Calcifediol | The risk or severity of adverse effects can be increased when Calcifediol is combined with Calcium polycarbophil. |
| Ergocalciferol | The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Calcium polycarbophil. |
| Cholecalciferol | The risk or severity of adverse effects can be increased when Cholecalciferol is combined with Calcium polycarbophil. |
| Paricalcitol | The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcium polycarbophil. |
| Dihydrotachysterol | The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Calcium polycarbophil. |
| Alfacalcidol | The risk or severity of adverse effects can be increased when Alfacalcidol is combined with Calcium polycarbophil. |
| Calcipotriol | The risk or severity of adverse effects can be increased when Calcipotriol is combined with Calcium polycarbophil. |
| Seocalcitol | The risk or severity of adverse effects can be increased when Seocalcitol is combined with Calcium polycarbophil. |
| Inecalcitol | The risk or severity of adverse effects can be increased when Inecalcitol is combined with Calcium polycarbophil. |
| Becocalcidiol | The risk or severity of adverse effects can be increased when Becocalcidiol is combined with Calcium polycarbophil. |
| Eldecalcitol | The risk or severity of adverse effects can be increased when Eldecalcitol is combined with Calcium polycarbophil. |
| 1alpha,24S-Dihydroxyvitamin D2 | The risk or severity of adverse effects can be increased when 1alpha,24S-Dihydroxyvitamin D2 is combined with Calcium polycarbophil. |
| Elocalcitol | The risk or severity of adverse effects can be increased when Elocalcitol is combined with Calcium polycarbophil. |
| Maxacalcitol | The risk or severity of adverse effects can be increased when Maxacalcitol is combined with Calcium polycarbophil. |
| Doxercalciferol | The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Calcium polycarbophil. |
| Vitamin D | The risk or severity of adverse effects can be increased when Vitamin D is combined with Calcium polycarbophil. |
| 1alpha-Hydroxyvitamin D5 | The risk or severity of adverse effects can be increased when 1alpha-Hydroxyvitamin D5 is combined with Calcium polycarbophil. |
| Tacalcitol | The risk or severity of adverse effects can be increased when Tacalcitol is combined with Calcium polycarbophil. |
| Previtamin D(3) | The risk or severity of adverse effects can be increased when Previtamin D(3) is combined with Calcium polycarbophil. |
| Tramadol | The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Tramadol. |
| Trospium | The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Trospium. |
| Oxyphenonium | The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Oxyphenonium. |